Stay One Move Ahead
Making effective
cancer drugs
available faster.
3D cell migration assay platform for cancer drug screening and validation
Making effective
90%
of drug candidates fail in human trials.
Late-stage resistance and poor predictivity derail the majority of therapies.
3–5%
of cancer drugs entering trials ever reach approval.
The success rate in oncology remains critically low.
€50–60B
lost annually in failed oncology R&D.
Billions are spent advancing therapies that ultimately do not translate.
50–100M
animals used every year in research.
Yet existing models still fail to reliably predict human cancer behaviour.
The Problem Isn’t Effort.
It’s Predictivity.
Cancer adapts. Resistance evolves.
Current models miss it.
Cymoplive Changes That.
Earlier, human-relevant detection of adaptive cancer behaviour.
Before clinical failure.
Our Pipeline
Breakthrough Discoveries
01
MarGel™
Our proprietary organ-like hydrogel engineered to recreate human-relevant physiological conditions and preserve tumour heterogeneity as observed in human cancers.
02
OncoTrix™
OncoTrix™ is a first-in-class platform that uses structured conditions to reveal functional adaptive behaviours of cancer cells missed by existing systems.
03
CellTraceD™
Live behavioural scoring that converts adaptive behaviour into actionable measures of cancer aggressiveness, drug efficacy pharmacodynamics, resistance/relapse risk, and combination performance.
Funding & Core Partners
